ICER finds Biogen’s new exorbitantly priced Alzheimer’s drug doesn’t match even an optimistic view of potential clinical benefits
Even with a rosy outlook on how Biogen’s new Alzheimer’s drug will help those with the debilitating and fatal disease, the Institute for Clinical and Economic Review on Wednesday said the $56,000 annual price tag “is not in reasonable alignment with its clinical benefits.”
In a new analysis, ICER said aducanumab would require an 85%-95% discount from the list price in order to be cost effective. Due to Biogen’s conflicting data and the “very small estimated impact” of aducanumab on the progression of moderate and severe Alzheimer’s disease, the watchdog said a fair price would be between $3,000 per year— if the drug is not as effective as promised —to $8,400, if it is.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
